Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab
OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS for trastuzumab plus chemotherapy was greater than MARGENZA plus chemotherapy for the small exploratory subgroup of patients homozygous for the CD16A 158V allele
The safety profile remains similar to what has been reported previously
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.